Dr. Reddy’s Laboratories has formed a licensing agreement with Takeda Pharmaceutical Company to market Vonoprazan tablets in India. Vonoprazan, an innovative, orally administered potassium-competitive acid blocker (PCAB), is used to treat reflux esophagitis and other acid-related disorders.
As reported by msn.com, the Hyderabad based pharmaceutical company announced that it has secured a non-exclusive patent licensing agreement with Takeda to commercialize this product. Dr. Reddy’s plans to market the tablets under its own brand name, Vono, in 10mg and 20mg dosages.
“The non-exclusive patent licensing agreement with Takeda underscores our commitment to providing innovative medicines to patients in India. Through strategic collaborations, we aim to address unmet medical needs and enhance the standard of care,” said MV Ramana, CEO of Branded Markets (India & Emerging Markets) at Dr. Reddy’s.
